Emergent BioSolutions infectious news

Emergent signed a follow-on contract with the CDC worth up to $911 million to supply 29.4 million doses of BioThrax to the U.S. Strategic National Stockpile through September 2021. BioThrax is approved for pre-or post-exposure prophylaxis of anthrax disease. The anthrax vaccine contains cell-free filtrates of microaerophilic cultures of an avirulent, non-encapsulated strain of Bacillus anthracis. Last year, CDC exercised an option to purchase all the remaining 44.8 million doses of BioThrax under a 2011 contract...